Effect of Telitacicept on Transitional Regulatory B Cells in Patients With Systemic Lupus Erythematosus
Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY
The effect of Telitacicept treatment on the changes of transitional regulatory B lymphocyte T1, T2B cell subsets and plasma blasts and the expression levels of cytokines IL-10, IL-35, April and BAFF in SLE.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 70
View:
• The diagnosis meets the 2019 EULAR/ACR classification criteria for SLE;
• Age 18-70 years old;
• To be on a stable SLE regimen, participants were required to receive standard treatment at least 1 month prior to treatment with a biologic (Telitacicept);
• Lupus activity Index score (SELENA-SLEDAI) ≥ 8 at screening;
• Positive anti-nuclear antibody or anti-DSDNA antibody;
• Combined antiphospholipid syndrome should meet the diagnostic criteria: that is, meet one clinical criterion and one laboratory criterion.
Locations
Other Locations
China
Yanfeng Hou
RECRUITING
Jinan
Contact Information
Primary
Yanfeng Hou, Dr.
yfhou1016@163.com
15168888165
Time Frame
Start Date: 2022-11-01
Estimated Completion Date: 2025-12-31
Participants
Target number of participants: 50
Treatments
Exposed group
Standard treatment for SLE + Telitacicept 160 mg qw
Control group
Standard treatment for SLE
Related Therapeutic Areas
Sponsors
Leads: Yanfeng Hou